Maxwell Biosciences

Maxwell Biosciences is a pioneering biotechnology startup with a firm commitment to developing next-generation anti-infectives. Their groundbreaking drug platform, known as CLAROMER™, has been validated by independent labs to effectively combat SARS-CoV-2 and a multitude of other viruses, along with fungal and bacterial pathogens. The company, founded in 2016 and headquartered in the United States, has already secured significant non-dilutive grants and awards, totaling over $35M, from various governments to validate their science and technology. This esteemed startup has gained notable traction with their lead drug candidate, demonstrating direct virucidal action against Herpes virus (HSV-1) and SARS-CoV-2. The extensive safety and efficacy data, including live mouse studies, have been conducted at reputable institutions such as Texas A&M and Baylor College of Medicine. Additionally, Maxwell Biosciences is raising substantial capital, evident from their recent $10.80M Seed Round investment in March 2022, with key investors including Keiretsu Forum Northwest, DecentraNet, Joseph Ventures, and Star Lake Bioventures. With a robust patent portfolio and a robust position in the fight against emergent viral pandemics and diverse infectious pathogens, Maxwell Biosciences is poised to make significant strides in advanced preclinical and human trials, offering potential opportunities for investors seeking impactful ventures in the biotechnology and healthcare sectors.